Keyphrases
Epidermal Growth Factor Receptor
100%
Apoptosis Induction
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
PI3K Inhibitor
100%
Differential Induction
100%
Apoptosis
71%
Mammalian Target of Rapamycin (mTOR)
71%
MEK Inhibitor (MEKi)
57%
Lung Cancer
42%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
42%
Myeloid Cell leukemia-1 (Mcl-1)
42%
Induced Apoptosis
28%
MTOR Inhibitor
28%
PI3K-mTOR Inhibitors
28%
Tumor
14%
Small Interfering RNA (siRNA)
14%
Acquired Resistance
14%
Tyrosine Kinase Inhibitor
14%
Xenograft Model
14%
Dual Inhibition
14%
Effective Strategies
14%
T790M
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Gefitinib
14%
NVP-BEZ235
14%
Erlotinib
14%
L858R
14%
HER2-amplified Breast Cancer
14%
Transgenic Mouse Model
14%
Activating mutation
14%
ERK Pathway
14%
MEK Signaling
14%
AKT Inhibitor
14%
Epidermal Growth Factor Receptor Inhibitors
14%
Intracellular Signaling
14%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Programmed Cell Death
100%
Mammalian Target of Rapamycin
63%
Downregulation
45%
Receptor Tyrosine Kinase Inhibitors
27%
MEK Inhibitor
27%
Upregulation
9%
Tyrosine Kinase Inhibitor
9%
Transgenics
9%
Small Interfering RNA
9%
Erlotinib
9%
Gefitinib
9%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Lung Cancer
37%
Epidermal Growth Factor Receptor Kinase Inhibitor
37%
Mitogen Activated Protein Kinase Kinase Inhibitor
37%
Mammalian Target of Rapamycin Inhibitor
25%
Breast Cancer
12%
Neoplasm
12%
Non Small Cell Lung Cancer
12%
Protein Tyrosine Kinase Inhibitor
12%
Small Interfering RNA
12%
Gefitinib
12%
Dactolisib
12%
Erlotinib
12%